Translating a better understanding of the microbiome, the large mass of micro-organisms that we all carry around in our gastrointestinal (GI) tract, our skin and elsewhere, into beneficial therapeutic products is proving to be a long and painstaking process. Still, it is one that may be attractive to researchers with a background in complex systems and processes.
Applying Scientific Rigor To Microbiome Therapeutics
PharmaBiome’s Second-Generation Candidates
Tomas de Wouters, one of In Vivo’s 2020 Rising Leaders, has taken on the complex challenge of the microbiome, aiming to design the next generation of microbiome therapeutic candidates targeted at host-microbial interactions.
More from Innovation
• By
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
• By
Appointed CEO 12 months ago, Anthony Costello wasted no time in orchestrating strategic change at Medidata. He talked to In Vivo about the art of the pivot and how to constantly push boundaries.
• By
Alto Neuroscience’s CEO, Amit Etkin, believes the company’s biomarker-based approach to psychiatric treatment is the way forward.
• By
The integration of digital health tools into clinical research and patient care is gaining momentum, and Merck KGaA, Darmstadt, Germany is not letting the grass grow under its feet. With an approach to digital biomarkers, the company is seeking to redefine how neurological diseases are monitored and managed.
More from In Vivo
• By
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.
• By
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
• By
João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.